Navigation Links
Multiple genes manage how people taste sweeteners
Date:8/20/2013

Genetics may play a role in how people's taste receptors send signals, leading to a wide spectrum of taste preferences, according to Penn State food scientists. These varied, genetically influenced responses may mean that food and drink companies will need a range of artificial sweeteners to accommodate different consumer tastes.

"Genetic differences lead to differences in how people respond to tastes of foods," said John Hayes, assistant professor, food science and director of the sensory evaluation center.

Based on the participants' genetic profile, researchers were able to explain the reactions of subjects in a taste test when they sampled Acesulfame-K -- Ace K -- in the laboratory. Ace K is a man-made non-nutritive sweetener commonly found in carbonated soft drinks and other products. Non-nutritive sweeteners are sweeteners with minimal or no calories.

While some people find Ace K sweet, others find it both bitter and sweet.

The researchers, who reported their findings in the recent issue of the journal, Chemical Senses, said that variants of two bitter taste receptor genes -- TAS2R9 and TAS2R31 -- were able to explain some of the differences in Ace K's bitterness.

These two taste receptor genes work independently, but they can combine to form a range of responses, said Alissa Allen, doctoral student in food science, who worked with Hayes.

Humans have 25 bitter-taste receptors and one sweet receptor that act like locks on gates. When molecules fit certain receptors like keys, a signal is sent to the brain, which interprets these signals as tastes -- some pleasant and some not so pleasant, Allen said.

In another study recently published in the journal Chemosensory Perception, Allen had 122 participants taste two stevia extracts, RebA -- Rebaudioside A -- and RebD -- Rebaudioside D. Stevia is a South American plant that has served as a sweetener for centuries, according to the researchers. While the plant is becoming more popular as a natural non-nutritive sweetener, consumers have reported of tastes from stevia-based sweeteners, including bitterness.

The researchers found that RebA and RebD bitterness varies greatly across subjects, but this was not related to whether or not participants found Ace K bitter. Likewise, variation in the TAS2R9 and TAS2R31 genes did not predict RebA and RebD bitterness. They also found that of the stevia extracts, the participants considered RebD to be much less bitter than RebA.

While stevia is growing in acceptance as a natural replacement for other sweeteners, manufacturers do not use the whole leaf. Instead, the leaf is ground up and certain parts of it are extracted and blended to make the sweetener.

"Our work suggests ingredient suppliers may want to consider commercializing RebD, as it provides similar sweetness to RebA with much less bitterness," said Hayes.

Hayes also said that researchers are just beginning to understand the molecular basis of taste perception.

"We've known for over 80 years that some people differ in their ability to taste bitterness, but we have only begin to tease apart the molecular basis of these differences in the last decade," Hayes said.


'/>"/>

Contact: Matthew Swayne
mls29@psu.edu
814-865-9481
Penn State
Source:Eurekalert

Related biology news :

1. Gene mutations caused by a fathers lifestyle can be inherited by multiple generations
2. Testing method promising for spinal cord injuries, multiple sclerosis
3. Study helps managers identify regions with multiple threat potential, including wildfires
4. Discovery of the gene responsible for multiple intestinal atresia in newborns
5. Cocktail of multiple pressures combine to threaten the worlds pollinating insects
6. Geology covers multiple disciplines and substantial territory in Aprils new postings
7. 23andMe identifies multiple genetic factors impacting development of nearsightedness
8. New research may aid treatment of multiple myeloma patients
9. New research network for multiple sclerosis research
10. Multiple sclerosis study reveals how killer T cells learn to recognize nerve fiber insulators
11. Nursing gerbils unravel benefit of multiple mothers in collective mammals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... up human tissue regeneration from small lab samples to full-size tissues, bones, even ... to establish a vascular system that delivers blood deep into the developing tissue. ...
(Date:3/22/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused on ... today that Dr. Miriam Kidron , Oramed,s ... "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock," ... Peptide Therapeutics (OPT) Boston Conference in Cambridge, ...
(Date:3/22/2017)... , March 22, 2017 /PRNewswire/ - FACIT ... (the "Company" or "Propellon"), a start-up created by ... anti-cancer therapeutics. FACIT,s investment, combined with non-dilutive capital, ... program. The seed funding enables Propellon to accelerate ... the Company for financing and/or entering a strategic ...
(Date:3/22/2017)... , ... March 21, 2017 , ... Okyanos Cell Therapy ... as part of their live events series, “Stem Cell Therapy: The Next Phase in ... under the 2013 Stem Cell Research and Therapy Act, Okyanos maintains a ...
Breaking Biology Technology: